Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626 1628 1629
This examiner grants 50% of resolved cases
Jared Barsky serves in Tech Center 1600 and Art Unit 1626. He has 941 resolved cases. His allowance rate is 50.2 percent. The median days to allowance for his granted patents is 950. This 950-day figure provides a timeline for applicants to expect when their cases are granted.
The interview lift for this examiner is 22.8 percent. This 22.8 percent lift is an increase when compared to the 50.2 percent baseline. It suggests that cases involving an interview have a higher probability of allowance than those that do not. For practitioners in Art Unit 1626, this data point indicates that direct communication is an effective strategy.
With 941 resolved cases, the data for this examiner is established. The allowance rate and median pendency describe the typical outcome and timing for his docket. The interview lift is a significant metric, showing a statistical benefit to conducting an interview during the prosecution process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17541461 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 18287690 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18553474 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | Non-Final OA | Trustees of Boston University |
| 18269390 | CLATHRATE IN WHICH EQUOL IS INCLUDED IN CYCLODEXTRIN, EQUOL-ABSORBENT COMPOSITION CONTAINING SAID CLATHRATE, AND PRODUCTION METHOD THEREFOR | Final Rejection | DAICEL CORPORATION |
| 18570552 | ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 18571412 | INJECTABLE, BIODEGRADABLE AND REMOVABLE POLYMER BASED DRUG SUSPENSION FOR ULTRA-LONG-ACTING DRUG DELIVERY | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18832236 | NOVEL REGIMEN FOR AUGMENTING AND EXTENDING TRANSPLANT TOLERANCE | Non-Final OA | The Regents of the University of California |
| 18853699 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | Non-Final OA | ELI LILLY AND COMPANY |
| 18866387 | COMPOSITIONS AND METHODS USING A COMBINATION OF FISETIN AND QUERCETIN FOR CELLULAR ENERGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18556564 | PROTEASE INHIBITORS AND METHODS OF USE | Final Rejection | The Cleveland Clinic Foundation |
| 18712069 | PROCESS FOR PRODUCTION OF VITAMIN A | Non-Final OA | DSM IP ASSETS B.V. |
| 17442968 | Tip60 Inhibitors and Methods of Use for Cardiovascular Disease | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18851253 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Non-Final OA | Novartis AG |
| 17910613 | METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS | Final Rejection | University of Virginia Patent Foundation |
| 18392419 | Artemisia anti-bacterial compositions and methods of use for inhibition of cells of Mycobacterium species | Non-Final OA | The Penn State Research Foundation |
| 18105511 | USE OF DELTA-8-THC TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | Non-Final OA | UNIVERSITY OF SOUTH CAROLINA |
| 18000471 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | Final Rejection | University of Maryland, Baltimore |
| 18493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Final Rejection | Boehringer Ingelheim International GmbH |
| 18553858 | METHOD FOR CONTROLLING DISEASE-TRANSMITTING INSECTS USING CONDENSED HETEROCYCLIC COMPOUND | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18711827 | DIALYSIS FLUID COMPRISING KETONE BODIES FOR THE TREATMENT OF CANCER | Final Rejection | GAMBRO LUNDIA AB |
| 18292464 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | Non-Final OA | Texas Heart Institute |
| 18863675 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | Non-Final OA | Janssen Pharmaceutica NV |
| 17759992 | TREATMENT OF MENORRHAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Final Rejection | Georgetown University |
| 18202033 | COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING PRIMARY SCLEROSING CHOLANGITIS | Final Rejection | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD. |
| 18138375 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | Non-Final OA | Albireo AB |
| 18417748 | METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING | Final Rejection | AltaThera Pharmaceuticals LLC |
| 18126561 | METHODS OF ADMINISTERING SOTALOL HYDROCHLORIDE | Final Rejection | AltaThera Pharmaceuticals LLC |
| 18527676 | COMPOSITION FOR TREATING ACUTE BRAIN INJURY OR NEURODEGENERATIVE DISEASE, METHOD OF MAKING, AND USE THEREOF | Final Rejection | MOREHOUSE SCHOOL OF MEDICINE |
| 18553333 | A PI3K-DELTA INHIBITOR FOR THE TREATMENT OF PANCREATIC CANCER | Non-Final OA | IONCTURA SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy